Cerebras Systems (CBRS) stock has witnessed some volatility since listing in May 2026. After an initial rally to 52-week highs of $386, CBRS stock touched lows of $160.8. However, in what seems like profit booking after the IPO, the stock has crawled higher to current levels of $252.
With Cerebras recently reporting Q2 numbers, there appears to be an increase in investor interest in this AI infrastructure company. Chase Coleman III's Tiger Global Management has initiated new positions in Cerebras Systems with the addition of three million shares with a market value of $663 million.
The significant stake comes at a point when Cerebras is likely to witness accelerated growth. To put things into perspective, the company’s manufacturing capacity is expected to increase by more than 10x in 2026. At the same time, Cerebras has increased its data center capacity (live and under contract) for delivery to more than 600 MW by the end of 2027. Cerebras also has a pipeline of data center opportunities in gigawatts. With these factors in consideration, it’s likely that CBRS stock will remain in an uptrend.
About Cerebras Stock
Headquartered in Sunnyvale, Cerebras is an artificial intelligence infrastructure company. The company’s full-stack hardware and software platform is designed to complete AI tasks significantly faster than comparable GPU-based solutions.
The company’s business is divided into two operational segments: Hardware and Cloud & Other Services. In the hardware business, the company’s Cerebras WSE is claimed to be the fastest AI processor ever brought to market in high volumes.
For the first six months of FY26, Cerebras reported revenue growth of 84.2% on a year-on-year (YoY) basis to $373.5 million. Also, supported by the initial public offering, Cerebras ended Q2 with a strong cash buffer of $8.5 billion. With $850 million available under the company’s revolving credit facility, the liquidity buffer has swelled to $9.4 billion.
After some correction following a strong listing, CBRS stock has been trending higher with returns of 21% in the last month. The recovery has been on the back of robust growth and a strong outlook.
Strong Foundation for Growth
It’s worth noting that Cerebras reported a remaining performance obligation (RPO) of $25.4 billion as of June 2026. As the company’s RPO swells, there is visibility for sustained growth.
For FY26, the company has guided for revenue of $885 million with a core gross margin of 42% (mid-range). While operating losses are likely to persist, that’s unlikely to be a concern. Cerebras is targeting a 60% core gross margin in the coming years. Therefore, as the phase of big investments is completed and with operating efficiencies, there is visibility for healthy cash flows in the next few years.
Another important point from a margin expansion perspective is that Cerebras reported services revenue growth of 281% on a year-on-year (YoY) basis to $126 million. This segment allows the company to generate recurring revenue from its cloud services business.
In terms of risk, a significant portion of the company’s revenue comes from OpenAI and Amazon (AMZN) Web Services. However, the company’s CEO, Andrew Feldman, believes that “OpenAI will shrink as a percentage” of revenue over time.
Overall, with over $9 billion in liquidity buffer, swelling RPO, and structural industry tailwinds, Cerebras is positioned for robust growth. At the same time, as the margin expansion story unfolds, the business is likely to deliver healthy cash flows.
What Do Analysts Say About CBRS Stock?
Based on 11 analysts with coverage, CBRS stock has a consensus “Strong Buy” rating. While eight analysts have a “Strong Buy” rating for the stock, one has a “Moderate Buy,” and two have a “Hold” rating.
The mean price target of $283.91 represents a potential upside of 35% from current levels. Further, the most bullish price target of $330 suggests that CBRS stock could climb as much as 56% from here.
On the date of publication, Faisal Humayun Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.